Skip to Primary Navigation

FTC resolves Express Scripts case with ‘landmark settlement’

A photo of seal on the US Federal Trade Commission on wall of headquarters in Washington, DC.
Photo: Kevin Carter/Getty Images

The pharmacy benefits manager has copped to artificially inflating the list price of drugs by using unfair rebating practices.

The Federal Trade Commission (FTC) has announced a “landmark settlement” with Cigna Group’s Express Scripts, Inc., and its affiliated entities (collectively “ESI”), one of the nation’s largest pharmacy benefit managers.

The settlement requires ESI to adopt “fundamental changes” to its business practices that increase transparency and bring millions of dollars

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience